The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
A phase 1/2 study with open-label, dose escalation phase followed by single-arm expansion at the maximum tolerated dose to assess the safety, tolerability, pharmacokinetics, pharmacodynamics, and efficacy of NT219 injection alone and in combination with cetuximab in adults with advanced solid tumors and head and neck cancer.
 
Alberto Bessudo
No Relationships to Disclose
 
Ezra E.W. Cohen
Consulting or Advisory Role - Bayer; BioNTech; Eisai; Gilead Sciences; Merck; MSD; Regeneron
 
Rodolfo Gutierrez
Research Funding - Immunocore (Inst); Immunocore (Inst)
 
Daniel H. Johnson
Leadership - BrightPath Biotheraputics
Honoraria - BrightPath Biotheraputics
Speakers' Bureau - Bristol-Myers Squibb/Pfizer
 
Ari Rosenberg
Consulting or Advisory Role - EMD Serono; Nanobiotix
 
Ammar Sukari
Stock and Other Ownership Interests - Merck
Honoraria - Merck Serono
Consulting or Advisory Role - Genentech
Speakers' Bureau - Eisai
 
Salomon M. Stemmer
Stock and Other Ownership Interests - canfite; CTG Pharma; DocBoxMD; tyrnovo; VYPE
Research Funding - AstraZeneca (Inst); BiolineRx (Inst); Bristol-Myers Squibb (Inst); Can-Fite BioPharma (Inst); Clovis Oncology (Inst); CTG Pharma (Inst); Exelixis (Inst); Geicam (Inst); Halozyme (Inst); Incyte (Inst); Lilly (Inst); Moderna Therapeutics (Inst); MSD (Inst); Puma Biotechnology (Inst); Rafael Pharmaceuticals (Inst); Roche (Inst); Silenseed (Inst); SynCoreBio (Inst); Taiga (Inst); Teva (Inst); Tiziana Life Sciences (Inst)
Patents, Royalties, Other Intellectual Property - check point inhibitors; combo patent; ctg; vype
 
Benjamin Adam Weinberg
Employment - Apple (I)
Stock and Other Ownership Interests - Apple (I)
Honoraria - Rafael Pharmaceuticals
Consulting or Advisory Role - AstraZeneca/Daiichi Sankyo; Bayer; HalioDx
Speakers' Bureau - AstraZeneca; Bayer; Diiachi Sankyo; HalioDx; Lilly; Sirtex Medical; Taiho Pharmaceutical
Research Funding - Abbvie (Inst); Ipsen (Inst); Isofol Medical (Inst); Novartis (Inst)
Expert Testimony - AstraZeneca
Travel, Accommodations, Expenses - Boehringer Ingelheim; Caris Life Sciences
 
Hadas Reuveni
Employment - Purple Biotech; TyrNovo
Leadership - Purple Biotech; TyrNovo
Stock and Other Ownership Interests - Purple Biotech; TyrNovo
Patents, Royalties, Other Intellectual Property - co-inventor on TyrNovo's patents
 
Michael Schickler
Employment - Purple Biotech
Leadership - Purple Biotech
Stock and Other Ownership Interests - Purple Biotech
Consulting or Advisory Role - Accellta; Immunorizon
Travel, Accommodations, Expenses - Purple Biotech
 
Bertrand C. Liang
Employment - Purple Biotech
Leadership - Purple Biotech
Stock and Other Ownership Interests - Kitov Pharmaceuticals
Consulting or Advisory Role - Kitov Pharmaceuticals
Research Funding - Purple Biotech
Travel, Accommodations, Expenses - Kitov Pharmaceuticals